PPT-Antiangiogenic Agents in Advanced NSCLC

Jared Weiss MD Assistant Professor of Medicine Division of Hematology and Oncology University of North Carolina School of Medicine Attending Physician UNC Lineberger Comprehensive Cancer . Gandara. , MD. University of California, Davis . Comprehensive Cancer Center. Biomarker-driven Phase III Clinical Trials: . Practical . & . Design Considerations. Clinical trial . d. esigns that define the. Renato G. Martins, MD, MPH. Medical Director, Thoracic/Head and Neck; General Oncology and Hematology. Seattle Cancer Care Alliance. July 28, 2015. 11:30 am – 12:30 pm, EST. ICLIO e-Course 02. Objectives. MD. The Evolving Treatment Landscape in NSCLC: Congress Updates. Outline of Talk. Provide a brief overview of current advances in the treatment of NSCLC. EGFR-targeted agents . ALK-EML4 targeted agents . The Coming Paradigm Shift. Faculty. Suresh S. Ramalingam, MD. Professor of Hematology/Oncology . Director, Lung . Cancer Program . Winship Cancer Institute. Emory University. Atlanta, . Georgia. Program Goals. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.. Dr Tan . Jiunn. Liang. Clinical Specialist (Respiratory Medicine). Department of Medicine. Universiti. Malaya Medical Centre. Disclaimer. This program is provided as a service to the medical profession and represents the opinions of the speakers, not necessarily those of Merck or MSD or its affiliates. The Role of Antiangiogenic Agents in the Changing Treatment Paradigm of NSCLC: Expert Perspectives Moderator Solange Peters, MD, PhD Chair, Medical Oncology Department of Oncology Centre Hospitalier Universitaire Vaudois (CHUV) The Cancer genome atlas (TCGA) and the search for a CUP genetic/epigenetic signature Manel Esteller , MD, PhD. Director, Josep Carreras Leukaemia Research Institute (IJC) Director, Cancer Epigenetics and Biology Program (PEBC) Beth . Eaby. -Sandy, MSN, CRNP, OCN. ®. Nurse Practitioner. Abramson . Cancer Center of the University of Pennsylvania. Disclosure of Conflicts of Interest. Beth . Eaby. -Sandy, MSN, CRNP, . O. CN. ®. proceedings from the live CME event and may include . the use of trade names and other raw, unedited content. . Moderator. Neil Love, MD. Faculty . Oncology Grand Rounds. . Emerging Strategies in Non-Small Cell Lung Cancer. Abramson Cancer Center . University of Pennsylvania. Philadelphia, Pennsylvania. Keeping Up in NSCLC: Actionable Biomarkers and Their Impact on Treatment. Rasheda Persinger, MSN, AGNP-C, AOCNP. Lead Nurse Practitioner. . 5. th. most commonly diagnosed cancer in Australia. 8.9% of new cancer diagnoses. In 2009: . 10,193 cases (. 6034 . men, 4159 women). Projection to . 2020.  . 13,640. Mortality. In 2010 most common cause of cancer death. Professor Rachel Butler. The genomic complexity of advanced NSCLC. Jordan et al. Cancer Discovery (2017). >50% NSCLC now have actionable variant. Treatment algorithm. NHSE: National Genomic Test Directory. Intervista a Federico . Cappuzzo. Background:. Programmed death-ligand 1 (PD-L1) expression on tumor cells (TC) or tumor-infiltrating immune cells (IC) is associated with OS, PFS and ORR in pts with advanced NSCLC treated with atezolizumab (anti-PDL1, MPDL3280A; Spigel et al, Spira et al, ASCO 2015), indicating that PD-L1 expression on both TC and IC is important for anti-tumor immunity. However, these 2 distinct expression patterns suggest the existence of previously unidentified NSCLC subtypes with distinct immunologic profiles. .